Formulation and Evaluation of Transdermal Patches of Nitrendipine Eudragit RLPO and RSPO Using Rate Controlling Polymers

This study aims at formulation evaluation of nitrendipine transdermal patch to mitigate hypertension. In total, six formulations of transdermal patches were prepared, and they were evaluated for various parameters. The thickness of the patch ranged from 89 ± 2 to 98 ± 6 ?m. The folding endurance was observed to be extended from 178 ± 5 to 225 ± 7. The % moisture content was varied from 5.12 ± 0.22 to 5.69 ± 0.32% while the moisture uptake ranged from 3.12 ± 0.32 to 3.96 ± 0.23%. In addition, the tensile strength was estimated as 0.45 ± 0.03 to 0.58 ± 0.03 kg/cm2. The % drug content was found to be maximum for F2 formulation which is about 99.12 ± 0.23% and lowest in the case of F1 formulation which is about 96.65 ± 0.15%. The in vitro % drug release was noticed to be 99.45 % in F1 and F6 formulations. Although the % drug release is better for F1 and F6, the F2 formulation is considered to be more superior and ideal by comparing between above-mentioned parameters.